

COVID-19 and RSV vaccines

Fiona Havers, MD, MHS, FIDSA
Emory University School of Medicine

October 6, 2026

COVID-19 vaccines



COVID-19 Vaccination rates are low in all groups


Vaccination coverage for 2025-26 vaccine*:

Children:	<10%
Pregnant individuals:	11%
Adults ≥ 18 years:	17.8%
Adults ≥ 65 years**:	23%

Lower in Hispanic and Black individuals



Myth: COVID-19 isn't a major problem any more



- **Fact:** COVID-19 contributes to hundreds of thousands of hospitalizations and thousands of deaths in the US each year, most in **adults ≥65 years**
- COVID-19 causes heart attacks, strokes and heart failure
- Vaccines reduce hospitalization risk

Myth: My baby is healthy, so doesn't need a COVID-19 vaccine



Fact: Infants and children <2 are at high risk for COVID-19 hospitalization because of their age alone.

Infants **<6 months** protected by maternal vaccine during pregnancy (ACOG recommendation)

American Academy of Pediatrics **recommends** COVID-19 vaccine for:

- All infants and children **ages 6 – 23 months**
- Children ages **2-18 years in certain risk groups**
- Other children 2 - 18 years not at increased risk whose parent or guardian desires protection should **be offered** a COVID-19 vaccine.



Myth: COVID-19 vaccines aren't safe in pregnancy

Fact: COVID-19 vaccines have been extensively studied in pregnancy and are considered safe.

FACT: COVID-19 can be dangerous for both mothers and babies during pregnancy.

ACOG recommendation: COVID-19 vaccination at any time during pregnancy

Pregnant individuals are at higher risk for **severe outcomes** from COVID-19

Vaccination during pregnancy protects **infants <6 months who are too young to be vaccinated**

COVID-19 immunization recommendations

COVID-19



**Children and
Adolescents
0-18 years**

All young children
ages 6-23 months and
children 2-18 years in
certain risk groups or if
desired



Pregnancy

Annual updated
COVID-19 vaccine



Adults 19-64 years

Annual updated
COVID-19 vaccine



Older Adults 65+ years

Annual updated
COVID-19 vaccine for
adults 65+, followed by
a second dose 6 months
later to boost protection



Immunocompromised

Annual updated
COVID-19 vaccine for
those ages ≥ 6 months



Healthcare Personnel

Annual updated
COVID-19 vaccine



RSV vaccines



RSV is the leading cause of hospitalization in U.S. infants

Two ways to protect babies:

Vaccinate mother during pregnancy (ACOG)

One-time RSV vaccine in first eligible pregnancy if 32-36 weeks pregnant, given between September 1 and March 1

Monoclonal antibodies (nirsevimab and clesrovimab) (AAP)


- All infants <8 months, if no protection from RSV vaccine during pregnancy
- Children 8-19 months in certain risk groups

Before RSV immunizations, 58,000 – 80,000 children <5 were hospitalized in the US each year from RSV

Highest risk in young infants

New products dramatically reduce risk of hospitalization in infants

RSV is under-recognized in adults



- Frequent cause of severe respiratory illness in older adults
- Lower awareness of RSV in adults among healthcare providers and the public
- Vaccines first available in 2023

Adult RSV Recommendations

WHO:

- **AAFP:**
 - All adults **≥75 years**
 - Adults **50-74** years at increased risk for severe RSV disease
- **IDSA:** Immunocompromised persons ≥18 years (<18 years shared decision making)
- **ACOG: Pregnant persons** at 32-36 weeks' gestation to prevent RSV in infants aged <6 months between Sept 1 and March 1 (Pfizer vaccine only)]

WHAT:

- **Single dose** (not an annual vaccine)
- 3 licensed vaccines





When do adults need another RSV shot?

- Entering 4th season with RSV vaccines available
- Vaccine protection wanes over multiple seasons

What about adults ages 18-49 (and older children) with high-risk medical conditions?

- FDA-approved vaccines for high-risk adults 18-49
 - No routine recommendation for this group
 - IDSA recommendation:
 - 1 dose immunocompromised adults 18-49
 - Immunocompromised children <18: Shared clinical decision

ALIGNED WITH EVIDENCE AND GUIDANCE FROM:



	 Influenza (flu)	 Respiratory syncytial virus (RSV)	 COVID-19
 Children and Adolescents 0-18 years	Annual flu vaccine for all children 6 months+	All infants <8 months, if no protection from RSV vaccine during pregnancy and children 8-19 months in certain risk groups	All young children ages 6-23 months and children 2-18 years in certain risk groups or if desired
 Pregnancy	Annual flu vaccine (avoid nasal spray flu vaccine)	One-time RSV vaccine in first eligible pregnancy if 32-36 weeks pregnant, given between September 1 and March 1	Annual updated COVID-19 vaccine
 Adults 19-64 years	Annual flu vaccine for all adults ages 19+	One-time RSV vaccine for adults ages 50-74 at increased risk of severe RSV	Annual updated COVID-19 vaccine
 Older Adults 65+ years	Annual flu vaccine for all adults, enhanced flu vaccine (high dose, adjuvanted, recombinant, or mRNA) for 65+, if possible	One-time RSV vaccine recommended for adults ages 50-74 at increased risk and all adults age 75+	Annual updated COVID-19 vaccine for adults 65+, followed by a second dose 6 months later to boost protection
 Immunocompromised	Annual flu vaccine for those ages ≥6 months (avoid nasal spray flu vaccine)	Single dose of RSV vaccine for those ages ≥18 years and for those ages <18 years, administration should be guided by shared decision making	Annual updated COVID-19 vaccine for those ages ≥6 months
 Healthcare Personnel	Annual flu vaccine	Follow age- and risk-based RSV vaccine recommendations	Annual updated COVID-19 vaccine

Respiratory Virus Immunization Recommendations

Thank you

Three RSV vaccines approved for adults in the U.S.

Vaccine	Manufacturer	Type	Year	FDA approval			
				60 years	50 – 59 years increased risk	18-49 years increased risk	Pregnant persons
Abrysvo*	Pfizer	Subunit	2023	✓	✓	✓	✓
Arexvy*	GSK	Subunit	2023	✓	✓	✓	
mResvia	Moderna	mRNA	2024	✓	✓	✓	

*WARNINGS and PRECAUTIONS: The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with AREXVY and ABRYSSVO.

COVID-19 vaccines approved for adults in the U.S.

Currently available COVID-19 vaccine products (U.S., 2026–2027)^{1,40}

Product (manufacturer)	Vaccine type/platform	FDA-approved indication	Practice notes
Spikevax® (Moderna)	mRNA	≥65 years, OR 6 months to 64 years with ≥1 underlying condition, conferring high risk for severe COVID-19	Only FDA-approved product for 6 months to 4 years.
Comirnaty® (Pfizer-BioNTech)	mRNA	≥65 years, OR 5 to 64 years with ≥1 underlying condition	Not approved for 6 months to 4 years; the prior emergency use authorization for that age group has been withdrawn.
mNexspike® (Moderna)	mRNA	≥65 years, OR 12 to 64 years with ≥1 underlying condition	Dose volume (0.2 mL) differs from Spikevax (0.5 mL)—do not interchange without checking.
Nuvaxovid™ (Novavax)	Protein subunit (adjuvanted)	≥65 years, OR 12 to 64 years with ≥1 underlying condition	Non-mRNA option for patients who prefer it.

Pediatric indications shown for context only; this guidance focuses on adults ≥19 years.